vs
Side-by-side financial comparison of GAXOS.AI INC. (GXAI) and Ovid Therapeutics Inc. (OVID). Click either name above to swap in a different company.
GAXOS.AI INC. is the larger business by last-quarter revenue ($1.2M vs $718.0K, roughly 1.7× Ovid Therapeutics Inc.). On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs 844.7%).
GXAI vs OVID — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $718.0K |
| Net Profit | $-957.9K | — |
| Gross Margin | — | — |
| Operating Margin | -99.0% | — |
| Net Margin | -77.2% | — |
| Revenue YoY | 94996.3% | 844.7% |
| Net Profit YoY | -15.1% | 204.4% |
| EPS (diluted) | $-0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $718.0K | ||
| Q3 25 | $498.3K | $132.0K | ||
| Q2 25 | $171.0K | $6.3M | ||
| Q1 25 | — | $130.0K | ||
| Q4 24 | — | $76.0K | ||
| Q3 24 | — | $173.0K | ||
| Q2 24 | $0 | $169.0K | ||
| Q1 24 | — | $148.0K |
| Q4 25 | $-957.9K | — | ||
| Q3 25 | $-1.0M | $-12.2M | ||
| Q2 25 | $-749.4K | $-4.7M | ||
| Q1 25 | — | $-10.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-14.0M | ||
| Q2 24 | $-809.2K | $8.5M | ||
| Q1 24 | — | $-11.7M |
| Q4 25 | -99.0% | — | ||
| Q3 25 | -263.9% | -9487.1% | ||
| Q2 25 | -574.8% | -80.9% | ||
| Q1 25 | — | -9653.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -7645.1% | ||
| Q2 24 | — | -12140.2% | ||
| Q1 24 | — | -11768.2% |
| Q4 25 | -77.2% | — | ||
| Q3 25 | -201.0% | -9210.6% | ||
| Q2 25 | -438.3% | -74.7% | ||
| Q1 25 | — | -7873.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -8096.0% | ||
| Q2 24 | — | 5042.0% | ||
| Q1 24 | — | -7901.4% |
| Q4 25 | $-0.13 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | $-0.72 | $0.12 | ||
| Q1 24 | — | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $840.5K | $13.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $130.7M |
| Total Assets | $13.4M | $150.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $840.5K | $13.2M | ||
| Q3 25 | — | $20.6M | ||
| Q2 25 | — | $28.4M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | — | $26.3M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | $4.5M | $29.7M | ||
| Q1 24 | — | $30.8M |
| Q4 25 | $13.1M | $130.7M | ||
| Q3 25 | $14.1M | $44.7M | ||
| Q2 25 | $15.0M | $55.8M | ||
| Q1 25 | — | $59.3M | ||
| Q4 24 | — | $68.2M | ||
| Q3 24 | — | $76.3M | ||
| Q2 24 | $4.7M | $88.9M | ||
| Q1 24 | — | $78.3M |
| Q4 25 | $13.4M | $150.9M | ||
| Q3 25 | $14.3M | $63.8M | ||
| Q2 25 | $15.4M | $77.4M | ||
| Q1 25 | — | $81.7M | ||
| Q4 24 | — | $92.2M | ||
| Q3 24 | — | $102.7M | ||
| Q2 24 | $5.1M | $118.1M | ||
| Q1 24 | — | $131.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-733.1K | $-38.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-733.1K | $-38.3M | ||
| Q3 25 | $-1.1M | $-12.9M | ||
| Q2 25 | $-716.9K | $-4.8M | ||
| Q1 25 | — | $-10.3M | ||
| Q4 24 | — | $-56.0M | ||
| Q3 24 | — | $-15.0M | ||
| Q2 24 | $-738.5K | $-14.3M | ||
| Q1 24 | — | $-16.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-56.0M | ||
| Q3 24 | — | $-15.0M | ||
| Q2 24 | — | $-14.3M | ||
| Q1 24 | — | $-16.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -73719.7% | ||
| Q3 24 | — | -8676.9% | ||
| Q2 24 | — | -8455.0% | ||
| Q1 24 | — | -11287.2% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 93.4% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 12.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.67× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
